Literature DB >> 8143395

Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways.

J A Carrillo1, J Benítez.   

Abstract

We studied the oxidative and N-acetylator caffeine metabolic profile in 107 healthy Spanish volunteers. Smokers had significantly higher N-1- and N-3-demethylations activities than nonsmokers (p = 0.03 and p = 0.02, respectively), and the three caffeine demethylations indexes were strongly correlated with each other (r > 0.7; p < 0.001). Our in vivo studies suggest that CYP1A2 is involved, at least in part, in the primary N-demethylations of caffeine. A non-normal and possibly bimodal distribution was detected in the xanthine oxidase activity (p = 0.04), with about 4% of subjects deficient of this metabolic activity. The population exhibited a trimodal distribution of acetylator phenotype determined by use of the 5-acetylamino-6-amino-3-methyluracil/1-methylxanthine ratio (normality test; p = 0.004). Seventy subjects (65.4%) were phenotyped as slow acetylators. The mutated gene frequency was 0.81, which is similar to other white populations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143395     DOI: 10.1038/clpt.1994.30

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

2.  Distribution of xanthine oxidase activity in a Nigerian population.

Authors:  Ayorinde Adehin; Oluseye Oladotun Bolaji
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

3.  Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.

Authors:  N Brynne; Y Böttiger; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 4.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

5.  In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.

Authors:  Natasa Djordjevic; Juan Antonio Carrillo; Guillermo Gervasini; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-02-13       Impact factor: 2.953

6.  Caffeine Intake among Undergraduate Students: Sex Differences, Sources, Motivations, and Associations with Smoking Status and Self-Reported Sleep Quality.

Authors:  Aina Riera-Sampol; Lluis Rodas; Sonia Martínez; Hannah J Moir; Pedro Tauler
Journal:  Nutrients       Date:  2022-04-16       Impact factor: 6.706

7.  Xanthine oxidase activity is influenced by environmental factors in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2003-08-21       Impact factor: 2.953

8.  Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

Authors:  L Bertilsson; J A Carrillo; M L Dahl; A Llerena; C Alm; U Bondesson; L Lindström; I Rodriguez de la Rubia; S Ramos; J Benitez
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 9.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Determination of Urinary Caffeine Metabolites as Biomarkers for Drug Metabolic Enzyme Activities.

Authors:  Hyeong Jun Kim; Min Sun Choi; Shaheed Ur Rehman; Young Seok Ji; Jun Sang Yu; Katsunori Nakamura; Hye Hyun Yoo
Journal:  Nutrients       Date:  2019-08-19       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.